Skip to main content
Yuyu Pharma, Inc. logo

Yuyu Pharma, Inc. — Investor Relations & Filings

Ticker · 000220 ISIN · KR7000220004 KO Manufacturing
Open in API
Filings indexed 304 across all filing types
Latest filing 2020-03-30 Audit Report / Informat…
Country KR South Korea
Listing KO 000220

About Yuyu Pharma, Inc.

https://www.yuyu.co.kr/

Yuyu Pharma, Inc., established in 1941, is a healthcare company focused on the development, manufacturing, and marketing of pharmaceutical products. The company is committed to creating innovative therapeutics to address healthcare challenges and improve quality of life. Its research and development efforts are concentrated on key therapeutic areas, with a notable emphasis on treatments for central nervous system disorders, including Alzheimer's disease. The company operates through several divisions, including Yuyu Healthcare, which provides pharmaceutical-standard Original Design Manufacturer (ODM) and Original Equipment Manufacturer (OEM) services.

Recent filings

Filing Released Lang Actions
사업보고서 (2019.12)
Audit Report / Information Classification · 99% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Yuyu Pharma (유유제약) for the fiscal year 2019. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. It is not an Annual Report (10-K) as it lacks the broader management discussion and analysis (MD&A) and business overview typically found in a full 10-K, and it is not an announcement (RPA) because it contains the full financial data. FY 2019
2020-03-30 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed with the Financial Supervisory Service (FSS) in South Korea. It details the specific dates, quantities, and prices of shares repurchased by Yuyu Pharmaceutical. This falls under the category of a company reporting the execution of a share buyback program, which is classified as 'Transaction in Own Shares' (POS).
2020-03-26 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM) for Yuyu Pharma. It details the outcomes of voting on agenda items such as financial statement approval, dividend declarations, and director appointments. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2020-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Yuyu Pharma. It provides a summary of the audit opinion (which is 'unqualified' or 'proper') and key financial data (assets, liabilities, revenue, profit) for both consolidated and separate financial statements. It explicitly states that the audit report was received on 2020-03-18 and mentions that it will be reported at the upcoming general meeting of shareholders. Since this is a formal regulatory announcement of the audit results rather than the full, multi-page audit report document itself, it falls under the category of Audit Report / Information (AR). FY 2019
2020-03-18 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Yuyu Pharma, specifically detailing a 'Decision to Acquire Treasury Shares' (자기주식 취득 결정). This is a formal regulatory filing in South Korea regarding a share buyback program. According to the provided definitions, reports of a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2020-03-13 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Yuyu Pharmaceutical. It contains the agenda for the meeting, including the approval of financial statements, director appointments, and dividend proposals. It also includes detailed financial statements (balance sheet, income statement, cash flow, etc.) as part of the 'Management Reference' (경영참고사항) required for shareholders to review before the meeting. Since this is a formal notice and information package provided to shareholders for an upcoming AGM, it falls under the category of Proxy Solicitation & Information Statement.
2020-03-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.